Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer

Official title

JCOG1801: A Phase III Randomized Controlled Trial Comparing Surgery Plus Adjuvant Chemotherapy With Preoperative Chemoradiotherapy Followed by Surgery Plus Adjuvant Chemotherapy for Locally Recurrent Rectal Cancer (RC-SURVIVE Study)

Overview

JCOG1801 is a randomized phase III trial which was initiated in Japan in August 2019 to confirm the superiority of preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for local relapse-free survival over standard treatment, i.e. surgery plus adjuvant chemotherapy, for previously non-irradiated locally recurrent rectal cancer.

Detailed description

In all, 110 patients from 43 Japanese institutions will be recruited over a period of 6 years. Eligible patients would be registered and randomly assigned to each group with an allocation ratio of 1:1. The primary endpoint is local relapse-free survival. The secondary endpoints are overall survival, relapse-free survival, proportion of local relapse, proportion of distant relapse, proportion of patients with pathological R0 resection, response rate of preoperative chemoradiotherapy (preoperative chemoradiotherapy arm), pathological complete response rate (preoperative chemoradiotherapy arm), proportion of patients who completed the protocol treatment, incidence of adverse events (adverse reactions), and quality of life after surgery.

Interventions

• Drug Chemotherapy
  Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14) mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours. Capecitabine: 2000 mg/m2/day, twice daily, days 1-14 5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 c
• Radiation Preoperative radiotherapy
  Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)
• Other Procedure
  Surgery for Locally Recurrent Rectal Cancer (LRRC) will be performed within 42 days from registration for the patients in arm A, and between days 56 and 98 from the completion of the preCRT for the patients in arm B. Appropriate surgical procedure will be performed to achieve R0 resection, such as low anterior resection, super low anterior resection, intersphincteric resection, Hartmann procedure, rectal amputation, pelvic exenteration, tumor resection, or lateral lymph node dissection

Primary outcome measures

• Locally recurrent free survival [Time frame: 3-years after registration]

Secondary outcome measures (10)

• Overall survival (OS) [Time frame: 3-years after registration]
• Recurrence free survival (RFS) [Time frame: 3-years after registration]
• Local relapse rate [Time frame: 3-years after registration]
• Distant relapse rate [Time frame: 3-years after registration]
• R0 resection rate [Time frame: 1 month after surgery]
• Response rate of preoperative chemoradiotherapy (preCRT) [Time frame: before surgery]
• Pathological complete response rate [Time frame: 1 month after surgery]
• Completeness of the protocol treatment [Time frame: 8 months after surgery]
• Adverse event rate [Time frame: 3-years after surgery registration]
• QOL [Time frame: 3-years after registration]

Eligibility criteria

Inclusion criteria

• Histopathologically proven adenocarcinoma or adenosquamous carcinoma on the resected specimen of the initial rectal cancer or endoscopic biopsy from the initial rectal cancer.
• The main tumor location of the initial rectal cancer is upper, middle or lower rectum, or anal canal.
• Either of the following treatments was performed for the initial rectal cancer, and classified as R0/1 or ER (Endoscopical R)0/1 on pathological diagnosis.

i) Surgical resection (including local resection, with or without lymph node dissection).

ii) Endoscopic resection.

• Patients with distant metastasis during or after treatment for the initial rectal cancer, and radical surgical resection or radical radiotherapy performed more than 168 days before registration is eligible.
• Recurrent rectal cancer diagnosed by any of the following modalities after treatment for the initial rectal cancer.

i) The recurrent lesion is pathologically diagnosed. ii) Diagnosed as local recurrence by more than two modalities among contrast-enhanced CT, contrast-enhanced MRI, or positron emission computed tomography (PET).

iii) Chronological progression of the lesion seen on more than one modality among contrast-enhanced CT, MRI, or PET.

• The main tumor location is within pelvis as seen on contrast-enhanced CT and MRI if recurrent lesion is multiple, or recurrent lesions spread outside of pelvis continuously.
• LRRC is diagnosed with no following condition. i) Judged as resectable endoscopically. ii) Depth of invasion within the muscularis propria as seen on contrast-enhanced CT, MRI, or PET in case of recurrence inside the intestine iii) Solitary ovarian metastasis. iv) Recurrence of the common iliac lymph node alone.
• LRRC is diagnosed as resectable, and all the following conditions must be fulfilled:

i) No distant metastasis on contrast-enhanced CT (cM0). ii) Estimated circumferential resection margin >0 mm. iii) Leg amputation not required. iv) Preservation of the first sacral nerve possible.

• No prior surgery for recurrent rectal cancer.
• No prior pelvic irradiation for any malignancies.
• A patient who has received systemic chemotherapy for any malignancies and the final dose was administered more than 14 days ago.
• Age at registration is 20 to 80 years old.
• Eastern Cooperative Oncology Group (ECOG) performance status is 0 or 1.
• Measurable lesion is not mandatory.
• Adequate oral intake.
• Sufficient organ function. i) Neutrophil count >= 1,500/mm3 ii) Hemoglobin >= 9.0 g/dL iii) Platelet count >= 100,000/mm3 iv) Total Bilirubin =< 2.0 mg/dL v) Aspartate aminotransferase (AST) =< 100 U/L vi) Alanine Aminotransferase (ALT) =< 100 U/L vii) Cr =< 1.5 mg/dL
• Open surgery or laparoscopic surgery is planned.
• Written informed consent is obtained.

Exclusion criteria

• Synchronous or metachronous (within 5 years) malignancies except cancer with 5-year relative survival rate of 95% or more such as carcinoma in situ, intramucosal tumor, or early stage cancers.
• Infections requiring systemic treatment.
• Body temperature higher than 38 degrees Celsius at registration.
• Pregnant female, female within 28 days post-parturition, or lactating mother. Men with partners planning conception in the near future.
• Severe psychological disease.
• Continuous systemic corticosteroid or immunosuppressant treatment.
• Uncontrollable diabetes mellitus.
• Uncontrollable hypertension.
• Unstable angina pectoris, or history of myocardial infarction within 6 months.
• Uncontrollable valvular disease, dilated cardiomyopathy, or hypertrophic cardiomyopathy.
• Positive serum Hepatitis B (HB)s antigen or serum Hepatitis C Virus (HCV) antibody.
• Positive serum HIV antibody.
• Interstitial pneumonia, pulmonary fibrosis, or severe emphysema on chest CT.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

Japan · 45 centers

• Chiba Cancer Center — Chiba
• Gifu University School of Medicine — Gifu
• Saitama Medical University International Medical Center — Hidaka
• Kansai Medical University Hospital — Hirakata
• Hiroshima City Asa Citizens Hospital — Hiroshima
• Hiroshima City Hospital — Hiroshima
• Shimane University Faculty of Medicine — Izumo
• Ishikawa Prefectural Central Hospital — Kanazawa
• … and 37 more centers

Publications

• Hashimoto T, Tsukada Y, Ito M, Kanato K, Mizusawa J, Fukuda H, Tsukamoto S, Takashima A, Kanemitsu Y. Utility of circulating tumour DNA for prognosis and prediction of therapeutic effect in locally recurrent rectal cancer: study protocol for a multi-institutional, prospective observational study (JCOG1801A1, CAP-LR study). BMJ Open. 2023 Aug 16;13(8):e073217. doi: 10.1136/bmjopen-2023-073217. PMID 37586869
• Kadota T, Tsukada Y, Ito M, Katayama H, Mizusawa J, Nakamura N, Ito Y, Bando H, Ando M, Onaya H, Fukuda H, Kanemitsu Y. A phase III randomized controlled trial comparing surgery plus adjuvant chemotherapy with preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for locally recurrent rectal cancer: Japan Clinical Oncology Group study JCOG1801 (RC-SURVIVE study). Jpn J Clin PMID 32409830

Identifiers

NCT: NCT04288999 · JCOG1801

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗